Defective DNA double strand break response due to BRCA1 loss of function

Stable Identifier
R-HSA-9663199
DOI
10.3180/R-HSA-9663199.1
Type
Pathway
Species
Homo sapiens
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
Defective DNA double strand break response due to BRCA1 loss of function
Click the image above or here to open this pathway in the Pathway Browser
Germline mutations in the BRCA1 or BRCA2 tumor suppressor genes are implicated in up to 10% of breast cancers overall and 40% of familial breast cancers. Carriers of either BRCA1 or BRCA2 germline mutation are predisposed to hereditary breast and ovarian cancer (the HBOC syndrome), which is inherited in an autosomal dominant manner. Besides early onset breast and ovarian cancer, HBOC patients also have a modestly increased risk of developing other tumor types, including pancreatic, stomach, laryngeal, fallopian tube, and prostate cancer. The BRCA1 gene encodes a large protein of 1863 amino acids, which contains a RING finger domain at the N-terminus and two BRCT repeats at the C-terminus. The RING domain is responsible for heterodimerization with BARD1, which increases stability of BRCA1 and activates its E3 ubiquitin ligase activity. BRCA1 plays an important role in homology-directed repair of DNA double-strand breaks (DSBs). Brca1-null knockout mice die early during embryonic development and cells depleted of BRCA1 show genomic instability (reviewed by Roy et al. 2011). Cancer mutations that affect the RING domain of BRCA1 frequently result in the inability of BRCA1 to bind to BARD1 and participate in DNA DSB response (Wu et al. 1996, Ransburgh et al. 2010). Some mutations in the RING domain of BRCA1 were shown to affect the ubiquitin ligase activity of BRCA1 (Brzovic et al. 2001), but it is uncertain if the ubiquitin ligase activity is essential for the tumor suppressor role of BRCA1 (Shakya et al. 2011).
Literature References
PubMed ID Title Journal Year
22193408 BRCA1 and BRCA2: different roles in a common pathway of genome protection

Powell, SN, Roy, R, Chun, J

Nat. Rev. Cancer 2011
22034435 BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity

Ludwig, T, Lin, CS, Cole, F, Hirsch, S, Baer, R, Reid, LJ, Szabolcs, M, Jasin, M, Shakya, R, Ravi, K, Egli, D, Hicks, JB, deRooij, DG, Reczek, CR

Science 2011
11526114 BRCA1 RING domain cancer-predisposing mutations. Structural consequences and effects on protein-protein interactions

Meza, JE, Brzovic, PS, Klevit, RE, King, MC

J. Biol. Chem. 2001
8944023 Identification of a RING protein that can interact in vivo with the BRCA1 gene product

Phung, A, Bowcock, AM, Wu, LC, Hwang, LY, Wang, ZW, Baer, R, Yang, MC, Spillman, MA, Xu, XL, Tsan, JT

Nat. Genet. 1996
20103620 Identification of breast tumor mutations in BRCA1 that abolish its function in homologous DNA recombination

Ishioka, C, Toland, AE, Ransburgh, DJ, Parvin, JD, Chiba, N

Cancer Res. 2010
Participants
Events
Participates
as an event of
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Orlic-Milacic, M  (2020-09-30)
Reviewed
Baer, RJ  (2020-11-04)
Created
Orlic-Milacic, M  (2019-09-27)
Cite Us!